Immune Support IV

Key Research Papers and Clinical Trials

Important Disclaimer: The evidence provided does not contain studies specifically evaluating "Immune Support IV" as a defined therapeutic intervention. The available research focuses on various immune-related treatments in specific disease contexts rather than general immune support infusions.

Research Paper Summary

The available research papers primarily examine targeted immune therapies for specific conditions rather than general immune support interventions:

Cancer Immunotherapy Research:

• A 2026 review in Frontiers in Immunology examined the clinical trial landscape for PD-1-containing bispecific antibodies in gastric cancer, though specific sample sizes were not provided in the available evidence.
• A systematic review and meta-analysis published in Annals of Surgical Oncology (2026) evaluated surgical outcomes following immune checkpoint inhibitor treatment in resectable stage III and IV melanoma patients, but detailed methodology was not included in the evidence.
• Research published in Frontiers in Oncology (2026) investigated how body mass index and insulin levels predict survival in stage IV lung adenocarcinoma patients receiving EGFR-TKI therapy.

Other Immune-Related Research:

• A 2026 study in the journal Small examined gold nanoparticle-embedded metal-organic frameworks for treating atopic dermatitis, focusing on antioxidant activities rather than systemic immune support.
• Various other papers addressed specific immune-related interventions in distinct clinical contexts, including lung cancer treatment protocols and COPD management.

Clinical Trial Evidence

The clinical trials identified do not directly evaluate "Immune Support IV" formulations:

• NCT07220915: A Phase 3 trial (not yet recruiting) testing Panzyga to prevent infections during autoimmune therapy, representing the most relevant study to general immune support concepts.
• NCT06250335: An active Phase 2 study examining prebiotic diet effects combined with immune checkpoint therapy in melanoma patients.
• Several other trials focused on specific immune interventions for cancer treatment or transplant-related complications.

Evidence Limitations

The current evidence base lacks studies specifically evaluating standardized "Immune Support IV" formulations for general immune enhancement. Most available research examines targeted immune therapies for specific diseases rather than broad immune support interventions. More research would be needed to establish efficacy and safety profiles for general immune support infusion therapies.